Business Description
Chemomab Therapeutics Ltd
NAICS : 541714
SIC : 8731
ISIN : US16385C1045
Share Class Description:
STU:2QV0: ADRDescription
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 35.35 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -58.7 | |||||
3-Year EPS without NRI Growth Rate | -56.2 | |||||
3-Year FCF Growth Rate | -61.2 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 69.71 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.82 | |||||
9-Day RSI | 71.19 | |||||
14-Day RSI | 64.24 | |||||
6-1 Month Momentum % | 77.6 | |||||
12-1 Month Momentum % | 17.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.12 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.9 | |||||
Shareholder Yield % | -0.93 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -48.14 | |||||
ROA % | -35.9 | |||||
ROIC % | -361.35 | |||||
ROC (Joel Greenblatt) % | -1267.8 | |||||
ROCE % | -49.48 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.01 | |||||
Price-to-Tangible-Book | 2 | |||||
EV-to-EBIT | -0.99 | |||||
EV-to-EBITDA | -0.99 | |||||
EV-to-FCF | -1.03 | |||||
Price-to-Net-Current-Asset-Value | 2.27 | |||||
Price-to-Net-Cash | 2.46 | |||||
Earnings Yield (Greenblatt) % | -101.01 | |||||
FCF Yield % | -37.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chemomab Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.5 | ||
Beta | 0.14 | ||
Volatility % | 73.61 | ||
14-Day RSI | 64.24 | ||
14-Day ATR (€) | 0.052756 | ||
20-Day SMA (€) | 1.003 | ||
12-1 Month Momentum % | 17.46 | ||
52-Week Range (€) | 0.39 - 1.29 | ||
Shares Outstanding (Mil) | 14.36 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Chemomab Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Chemomab Therapeutics Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Chemomab Therapeutics Ltd Frequently Asked Questions
What is Chemomab Therapeutics Ltd(STU:2QV0)'s stock price today?
The current price of STU:2QV0 is €1.18. The 52 week high of STU:2QV0 is €1.29 and 52 week low is €0.39.
When is next earnings date of Chemomab Therapeutics Ltd(STU:2QV0)?
The next earnings date of Chemomab Therapeutics Ltd(STU:2QV0) is 2024-08-21.
Does Chemomab Therapeutics Ltd(STU:2QV0) pay dividends? If so, how much?
Chemomab Therapeutics Ltd(STU:2QV0) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |